Genentech’s tiragolumab maintains its TIGIT edge

Genentech’s anti-TIGIT mAb tiragolumab is living up to the hype it generated last year, producing the kind of checkpoint inhibitor combination benefit the industry has been seeking for years.

The question now is whether the market for tiragolumab — and other anti-TIGIT mAbs in development — will be limited to the subset of solid tumors expressing high levels of PD-L1...